One Week Adjuvant Radiotherapy for Breast Cancer

A Prospective Study of One Week Accelerated Hypo-fractionation Adjuvant Radiotherapy in High-risk Breast Cancer Patients

• Cancer is the second leading cause of death after cerebrovascular strokes and is a significant obstacle to each nation's future growth.
• Worldwide, Breast cancer is the most common cancer in women and the 5th leading cause of cancer related deaths that comes after lung cancer, colorectal cancer, liver cancer and gastric cancer.
• More than half of all breast cancer cases in the world occur in developing countries. Egypt has a high mortality rate from breast cancer, with a rate of 21.3 per 100,000 cases. Breast cancer is diagnosed at an advanced stage in 60 to 70% of cases in Egypt. The median age at diagnosis in Egypt is 48.5 years, which seems to be a decade younger than in Europe and North America.

Inclusion Criteria:

• Female patients 45 years of age or older who have had Oncoplastic Breast Surgery (OBS) or total mastectomy with adequate axillary clearance and a negative margin.
• Breast carcinomas that is invasive (TXN1-3M0, T0N2-3 M0, T1N2-3M0, T2N2-3M0, T3N0-3M0, T4N0-3M0) whatever type of tumors biology.
• All patients with locally advanced breast cancer who received neoadjuvant chemotherapy and underwent either oncoplastic breast surgery or modified radical mastectomy

Exclusion Criteria:

• Metastatic breast cancer at the time of diagnosis proved clinically or radiologically.
• Postoperative positive margin.
• Carcinomas in situ.
• Mesenchymal breast lesions.
• Locoregional recurrent breast cancer.
• Synchronous bilateral breast cancer.
• very early breast cancer (T1-2N0M0,T1N1M0).